Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin

Jiang,Shan; Chen,Xiaopin; Li,Chunyan; Zhang,Xingping; Zhang,Tao; Yue,Yujuan; Yang,Guang

doi:10.3892/mmr.2012.1074

Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin

Authors:
- Shan Jiang
- Xiaopin Chen
- Chunyan Li
- Xingping Zhang
- Tao Zhang
- Yujuan Yue
- Guang Yang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Endocrine and Breast Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China
Published online on: September 10, 2012 https://doi.org/10.3892/mmr.2012.1074
Pages: 1351-1354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiotherapy is the principal therapy for nasopharyngeal carcinoma (NPC) at early stages. A number of chemotherapeutic methods have been used to inhibit the progression of NPC at elevated stages. Suramin has been reported to inhibit the growth of certain tumor cells via various pathways. In the present study, we aimed to analyze the effects of suramin on the proliferation of NPC cells (CNE-2). Suramin was proved to demonstrate NPC cell growth-inhibiting effects both in a dose- and time-dependent manner. To determine the potential mechanisms of these effects, western blotting and flow cytometric analysis were performed. Suramin was found to have the potential to induce cell cycle arrest in S-phase CNE-2 cells. Additionally, we found that the OPN level may decrease in suramin-treated CNE-2 cells. The changes of certain apoptosis- and p-AKT-associated proteins possibly regulating the OPN expression were measured by western blotting. In conclusion, suramin may function as a potential agent for the adjunctive therapy of NPC.

View Figures

View References

1	Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
2	Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 20:264–269. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hawking F: Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 15:289–322. 1978. View Article : Google Scholar : PubMed/NCBI
4	Song S, Yu B, Wei Y, Wientjes MG and Au JL: Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res. 10:6058–6065. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ and Hotz HG: Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg. 11:171–178. 2007. View Article : Google Scholar : PubMed/NCBI
6	Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, et al: A phase II trial of suramin monthly × 3 for hormone-refractory prostate carcinoma. Cancer. 100:65–71. 2004.
7	Agrawal D, Chen T, Irby R, et al: Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. J Natl Cancer Inst. 94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
8	Rudland PS, Platt-Higgins A, El-Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62:3417–3427. 2002.PubMed/NCBI
9	Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
10	Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 55:483–90. 2012. View Article : Google Scholar : PubMed/NCBI
11	Gong M, Lu Z, Fang G, Bi J and Xue X: A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 272:148–159. 2008. View Article : Google Scholar : PubMed/NCBI
12	Geissinger E, Weisser C, Fischer P, Schartl M and Wellbrock C: Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res. 62:4820–4828. 2002.PubMed/NCBI
13	Yang G, Zhang Y, Wu J, Xiong J, Deng H, Wang J, Yang C and Zhu Z: Osteopontin regulates growth and migration of human nasopharyngeal cancer cells. Mol Med Rep. 4:1169–1173. 2011.PubMed/NCBI
14	Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL and Yuen AP: Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol. 31:555–558. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hui EP, Sung FL, Yu BK, et al: Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res. 14:7080–7087. 2008. View Article : Google Scholar : PubMed/NCBI
16	McCain DF, Wu L, Nickel P, Kassack MU, Kreimeyer A, Gagliardi A, Collins DC and Zhang ZY: Suramin derivatives as Inhibitors and activators of protein-tyrosine phosphatases. J Biol Chem. 279:14713–14725. 2004. View Article : Google Scholar : PubMed/NCBI
17	Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H and Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 77:292–300. 1996. View Article : Google Scholar
18	Kolfschoten GM, Hulscher TM, Pinedo HM and Boven E: Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer. 83:921–927. 2000. View Article : Google Scholar : PubMed/NCBI
19	Zhang G, He B and Weber GF: Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol. 23:6507–6519. 2003. View Article : Google Scholar
20	Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES and Lee SH: Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res. 65:686–691. 2005.PubMed/NCBI